News | July 31, 2025
Roche updates on Elevidys gene therapy for Duchenne muscular dystrophy in EU
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
NewCo’s pipeline includes five investigational medicines
For patients with resectable early-stage gastric and gastroesophageal junction cancers
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
This year, the OCTF focused on preparing a white paper on oral cancer elimination in India and updating its annual consensus guidelines
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
This certification validates the plant’s robust capabilities in manufacturing a wide range of sterile dosage forms
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas
Subscribe To Our Newsletter & Stay Updated
